In 2023, a study addressing the safety profile of upadacitinib over 15,000 patient-years in RA, PsA, ASpa, or atopic dermatitis was published, describing an increased risk of herpes zoster and elevated CPK levels, consistent with the overall safety profiles of JAK inhibitors; otherwise, no new safety risks were identified when compared to previous reports [8]. This evidence concerns the gene PIK3C2A and rheumatoid arthritis.